ADAG

$0.00

(

0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Adagene Inc

NASDAQ | ADAG

1.85

USD

$0.00

(

0.00%

)

At Close (As of Dec 18, 2025)

$84.84M

Market Cap

-

P/E Ratio

-0.64

EPS

$3.16

52 Week High

$1.30

52 Week Low

HEALTHCARE

Sector

ADAG Chart

Recent Chart
Price Action

ADAG Technicals

Tags:

ADAG Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$823K
Total Revenue $103K
Cost Of Revenue $926K
Costof Goods And Services Sold $926K
Operating Income -$36M
Selling General And Administrative $7.3M
Research And Development $29M
Operating Expenses $36M
Investment Income Net -
Net Interest Income $2.9M
Interest Income $3.8M
Interest Expense $852K
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $926K
Income Before Tax -$33M
Income Tax Expense -$18K
Interest And Debt Expense -
Net Income From Continuing Operations -$33M
Comprehensive Income Net Of Tax -
Ebit -$33M
Ebitda -$32M
Net Income -$33M

Revenue & Profitability

Earnings Performance

ADAG Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $89M
Total Current Assets $88M
Cash And Cash Equivalents At Carrying Value $85M
Cash And Short Term Investments $85M
Inventory -
Current Net Receivables $8.3K
Total Non Current Assets $1.5M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments -
Other Current Assets $2.6M
Other Non Current Assets -
Total Liabilities $39M
Total Current Liabilities $38M
Current Accounts Payable $4.2M
Deferred Revenue -
Current Debt -
Short Term Debt $18M
Total Non Current Liabilities $560K
Capital Lease Obligations $284K
Long Term Debt $417K
Current Long Term Debt $18M
Long Term Debt Noncurrent -
Short Long Term Debt Total $18M
Other Current Liabilities $16M
Other Non Current Liabilities -
Total Shareholder Equity $51M
Treasury Stock -
Retained Earnings -$311M
Common Stock $5.9K
Common Stock Shares Outstanding $36M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$30M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $926K
Capital Expenditures $34K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment $1.1M
Cashflow From Financing $3.8M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity $0
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$33M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$823K
Total Revenue $103K
Cost Of Revenue $926K
Costof Goods And Services Sold $926K
Operating Income -$36M
Selling General And Administrative $7.3M
Research And Development $29M
Operating Expenses $36M
Investment Income Net -
Net Interest Income $2.9M
Interest Income $3.8M
Interest Expense $852K
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $926K
Income Before Tax -$33M
Income Tax Expense -$18K
Interest And Debt Expense -
Net Income From Continuing Operations -$33M
Comprehensive Income Net Of Tax -
Ebit -$33M
Ebitda -$32M
Net Income -$33M

ADAG News

ADAG Profile

Adagene Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Adagene Inc. is a clinical-stage biopharmaceutical company based in Suzhou, China, specializing in the development of innovative monoclonal antibody therapies for oncology. Utilizing its proprietary technologies, the company is at the forefront of creating next-generation antibody drug candidates designed to enhance therapeutic efficacy while minimizing adverse effects in cancer treatment. With a promising pipeline of drug candidates that address significant unmet medical needs within the oncology space, Adagene is poised to make impactful contributions to the biopharmaceutical industry and improve outcomes for patients battling cancer.

LPTX
+368.57%
$2.05
VYNE
+48.99%
$0.60
PAVS
-13.47%
$0.01
YGMZ
-61.42%
$0.02
IRBT
+0.23%
$0.76
AVGO
-4.47%
$326.02
ASST
-4.60%
$0.82
AXDX
-61.36%
$0.03
ADAP
-15.14%
$0.05
VIVK
+10.58%
$0.05
ACHR
-4.65%
$7.58
SOND
-23.45%
$0.12
ATHA
+77.26%
$7.33
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
IVP
-5.80%
$0.04
SRM
+53.27%
$10.30
IREN
-7.67%
$33.78
AMD
-5.28%
$198.11
UDMY
+12.66%
$6.05
VHAI
0.00%
$0.00
CGC
+18.75%
$2.28
KDLY
-4.14%
$0.36
ITUB
-2.08%
$7.04
CPNG
-2.02%
$22.72
CSCO
-1.99%
$76.00
SMCI
-5.74%
$29.84
MSFT
-0.05%
$476.12
AKAN
-0.67%
$0.74
HBAN
+0.68%
$17.75
PLUG
+12.96%
$2.44
AFMD
-34.94%
$0.18
KOS
-5.01%
$0.91
WOK
-8.86%
$0.05
VMAR
-48.83%
$0.49
NGD
+1.21%
$8.33
AGNC
+1.06%
$10.44
ATPC
-9.58%
$0.12
HL
+2.05%
$19.41
QUBT
-9.31%
$10.22
GRYP
-10.38%
$1.38
BTE
+4.65%
$3.15
MSTR
-4.25%
$160.38
MODV
-25.22%
$0.43
CCL
-0.60%
$28.03
PINS
+0.38%
$25.88
BE
-12.14%
$76.97
RR
-5.50%
$3.43
MDLZ
-0.27%
$53.82
NOK
-1.11%
$6.22
NBIS
-6.79%
$75.45
CAN
-1.76%
$0.78
KEY
+1.06%
$20.80
EXK
+0.42%
$9.36
INFY
+2.53%
$18.22
IBRX
-2.31%
$2.11
META
-1.16%
$649.50
COUR
-1.25%
$7.84
SLB
+2.44%
$38.53
BMY
-1.25%
$53.55
SEE
-0.76%
$41.35
AZI
-3.74%
$1.80
MSS
-19.85%
$0.34
RIOT
-3.78%
$12.96
WFC
+0.43%
$92.59
BB
-2.96%
$4.26
FI
+0.93%
$68.33
FISV
+0.93%
$68.33
MU
+16.40%
$262.50
ALIT
+2.91%
$2.12
ET
+0.18%
$16.39
KHC
+0.28%
$24.75
SHOT
-74.37%
$0.39
OXY
+4.39%
$40.63
KO
+0.42%
$70.67
ZAPP
-46.30%
$0.15
AUR
-1.21%
$4.07
NKE
-2.13%
$65.69
MRK
+0.92%
$99.18
RZLT
-0.49%
$2.01
FLEX
-3.32%
$62.85
URG
+2.29%
$1.34
MIST
-2.27%
$2.15
ROIV
-1.04%
$22.70
GERN
+4.47%
$1.40
BSX
+1.64%
$94.48
LUV
-2.82%
$40.98
LRCX
-5.07%
$154.98
KMI
+1.21%
$26.65
DIS
-0.88%
$110.63
HLN
-0.30%
$9.82
HAL
+2.02%
$27.74
APH
-2.02%
$126.51
CRBG
-3.90%
$30.52
TSLA
+2.11%
$477.15
ETHE
-4.42%
$23.13
NVTS
-5.74%
$7.38
HPQ
-1.61%
$24.43
CFLT
+0.13%
$30.00
LPTX
+368.57%
$2.05
VYNE
+48.99%
$0.60
PAVS
-13.47%
$0.01
YGMZ
-61.42%
$0.02
IRBT
+0.23%
$0.76
AVGO
-4.47%
$326.02
ASST
-4.60%
$0.82
AXDX
-61.36%
$0.03
ADAP
-15.14%
$0.05
VIVK
+10.58%
$0.05
ACHR
-4.65%
$7.58
SOND
-23.45%
$0.12
ATHA
+77.26%
$7.33
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
IVP
-5.80%
$0.04
SRM
+53.27%
$10.30
IREN
-7.67%
$33.78
AMD
-5.28%
$198.11
UDMY
+12.66%
$6.05
VHAI
0.00%
$0.00
CGC
+18.75%
$2.28
KDLY
-4.14%
$0.36
ITUB
-2.08%
$7.04
CPNG
-2.02%
$22.72
CSCO
-1.99%
$76.00
SMCI
-5.74%
$29.84
MSFT
-0.05%
$476.12
AKAN
-0.67%
$0.74
HBAN
+0.68%
$17.75
PLUG
+12.96%
$2.44
AFMD
-34.94%
$0.18
KOS
-5.01%
$0.91
WOK
-8.86%
$0.05
VMAR
-48.83%
$0.49
NGD
+1.21%
$8.33
AGNC
+1.06%
$10.44
ATPC
-9.58%
$0.12
HL
+2.05%
$19.41
QUBT
-9.31%
$10.22
GRYP
-10.38%
$1.38
BTE
+4.65%
$3.15
MSTR
-4.25%
$160.38
MODV
-25.22%
$0.43
CCL
-0.60%
$28.03
PINS
+0.38%
$25.88
BE
-12.14%
$76.97
RR
-5.50%
$3.43
MDLZ
-0.27%
$53.82
NOK
-1.11%
$6.22
NBIS
-6.79%
$75.45
CAN
-1.76%
$0.78
KEY
+1.06%
$20.80
EXK
+0.42%
$9.36
INFY
+2.53%
$18.22
IBRX
-2.31%
$2.11
META
-1.16%
$649.50
COUR
-1.25%
$7.84
SLB
+2.44%
$38.53
BMY
-1.25%
$53.55
SEE
-0.76%
$41.35
AZI
-3.74%
$1.80
MSS
-19.85%
$0.34
RIOT
-3.78%
$12.96
WFC
+0.43%
$92.59
BB
-2.96%
$4.26
FI
+0.93%
$68.33
FISV
+0.93%
$68.33
MU
+16.40%
$262.50
ALIT
+2.91%
$2.12
ET
+0.18%
$16.39
KHC
+0.28%
$24.75
SHOT
-74.37%
$0.39
OXY
+4.39%
$40.63
KO
+0.42%
$70.67
ZAPP
-46.30%
$0.15
AUR
-1.21%
$4.07
NKE
-2.13%
$65.69
MRK
+0.92%
$99.18
RZLT
-0.49%
$2.01
FLEX
-3.32%
$62.85
URG
+2.29%
$1.34
MIST
-2.27%
$2.15
ROIV
-1.04%
$22.70
GERN
+4.47%
$1.40
BSX
+1.64%
$94.48
LUV
-2.82%
$40.98
LRCX
-5.07%
$154.98
KMI
+1.21%
$26.65
DIS
-0.88%
$110.63
HLN
-0.30%
$9.82
HAL
+2.02%
$27.74
APH
-2.02%
$126.51
CRBG
-3.90%
$30.52
TSLA
+2.11%
$477.15
ETHE
-4.42%
$23.13
NVTS
-5.74%
$7.38
HPQ
-1.61%
$24.43
CFLT
+0.13%
$30.00
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.